Cantargia completes toxicity study for IL1RAP-binding antibody CAN-10
Jan. 16, 2023
Cantargia AB has completed a GLP toxicity study for its anti-inflammatory IL1RAP-binding antibody CAN-10, showing that CAN-10 was well tolerated when administered over 6 weeks.
